PDS Biotechnology Corporation (PDSB) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call presents a mixed outlook. Positive aspects include new patents for PDS0101 and reduced net loss, suggesting improved financial health. However, significant risks exist, such as the VERSATILE-003 trial amendment and early-stage PDS01ADC trials. The Q&A session highlighted management's evasiveness on certain topics, raising concerns. Overall, the company's financial constraints and pending trial results maintain a neutral sentiment.
Key Financial Performance
Net Loss $7.3 million or $0.13 per basic and diluted share for Q1 2026, compared to $8.5 million or $0.21 per basic and diluted share for Q1 2025. The decrease in net loss was due to lower operating expenses.
Research and Development Expenses $3.5 million for Q1 2026, compared to $5.8 million for Q1 2025. The decrease was primarily due to lower clinical and manufacturing costs.
General and Administrative Expenses $3.1 million for Q1 2026, compared to $3.3 million for Q1 2025. The decrease was primarily due to lower professional fees.
Total Operating Expenses $6.5 million for Q1 2026, compared to $9.1 million for Q1 2025. The decrease was due to reductions in research and development as well as general and administrative expenses.
Net Interest Expense $0.8 million for Q1 2026, compared to $0.6 million for Q1 2025. The increase was not explained in the transcript.
Cash Balance $21.7 million as of March 31, 2026. No year-over-year comparison or reasons for change were provided.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
VERSATILE-003 trial amendment: Revised design to incorporate progression-free survival as an interim primary endpoint, potentially enabling a more efficient path to accelerated approval, shortening trial duration, and reducing costs.
PDS0101: Promising treatment for HPV16-positive head and neck cancer; requires only 5 doses and is subcutaneous. Demonstrated tolerability and survival data. Positioned to address unmet needs in HPV16-positive cancers.
PDS01ADC: Novel investigational IL-12 fused antibody drug conjugate showing promising results in prostate and colorectal cancer trials. Enhances T cell proliferation, potency, and longevity in tumor microenvironment.
Intellectual property expansion: New patents granted in the U.S. and Japan for PDS0101, extending market protection into the 2040s and adding broad composition of matter claims.
Financial performance: Net loss of $7.3 million for Q1 2026, an improvement from $8.5 million in Q1 2025. Decrease in R&D and general administrative expenses contributed to reduced operating expenses.
Pipeline focus: Advancing PDS0101 and PDS01ADC as key components of the immuno-oncology pipeline to address unmet needs in cancer treatment.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
VERSATILE-003 trial amendment: The amendment to the VERSATILE-003 trial design to incorporate progression-free survival as an interim primary endpoint could pose risks if the revised design does not meet FDA requirements or fails to demonstrate efficacy, potentially delaying approval and increasing costs.
HPV16-positive cancer treatment: The rapidly growing population of HPV16-positive patients and the absence of approved targeted therapies highlight a significant unmet need. However, the poor uptake of the HPV vaccine and other factors contributing to the increase in HPV16-positive cancers could challenge the effectiveness and adoption of PDS0101.
PDS01ADC trials: While promising results were reported for PDS01ADC in prostate and colorectal cancer trials, the therapy is still in early stages, and its efficacy and safety need further validation. Any setbacks in these trials could impact the company's pipeline and strategic objectives.
Intellectual property and market protection: Although new patents extend market protection for PDS0101 into the 2040s, potential challenges include patent disputes, regulatory hurdles, and competition from other therapies that could erode market exclusivity.
Financial performance: The company reported a net loss of $7.3 million for the quarter, with a cash balance of $21.7 million as of March 31, 2026. Sustained losses and limited cash reserves could constrain operational capabilities and strategic initiatives.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
VERSATILE-003 trial amendment: The trial design was revised to incorporate progression-free survival as an interim primary endpoint, potentially enabling a more efficient path to accelerated approval. This amendment may shorten the trial's duration, reduce overall costs, and accelerate the availability of treatment for HPV16-positive patients.
PDS0101 development: PDS0101 is being advanced as a promising treatment for HPV16-positive head and neck cancer, with unique characteristics such as requiring only 5 doses and being a subcutaneous therapy. The company is focused on addressing the unmet need in HPV16-positive cancers, which are rapidly increasing in the U.S. and EU.
PDS01ADC trials: Promising results were reported from trials for prostate and colorectal cancer. The therapy demonstrated potential to enhance the efficacy of existing treatments across multiple solid tumor types. The company is advancing PDS01ADC as a key component of its immuno-oncology pipeline.
Intellectual property for PDS0101: New patents were granted in the U.S. and Japan, extending market protection into the 2040s and adding broad composition of matter claims to existing protections across major markets.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What remains pending for the VERSATILE-003 restart enrollment activity, and is there a consideration of including subcutaneous KEYTRUDA as a combination partner?
A:The enrollment is pending the amendment of the protocol and re-engagement with the sites, which have remained supportive during the pause. The possibility of using subcutaneous pembrolizumab exists but is not the current target of research. The focus remains on intravenous pembrolizumab.
Q:What is the current landscape for HPV16-positive head and neck cancer, and are there any updates expected from the EGFR bispecific class?
A:The HPV16-positive head and neck cancer space remains relatively open, with PDS and BioNTech being the two late-stage studies in this area. No specific updates from the EGFR bispecific class were mentioned.
Q:When is the next data update expected for the colorectal cancer cohort Stage 2?
A:The next data update for the colorectal cancer cohort Stage 2 is anticipated by the end of the year.
Q:What are the benefits of the recent amendment to the VERSATILE-003 protocol, and what is the financial impact of these changes?
A:The amendment allows for a co-primary endpoint of PFS and median overall survival, potentially enabling accelerated review. Financially, the changes reduce costs by shortening the trial timeline and lowering the number of patients from 350 to 250 due to a change in randomization ratio from 2:1 to 1:1.
Q:What are the manufacturing needs for Versamune and the pipeline in the near term and beyond potential early commercialization?
A:The manufacturing process for Versamune is straightforward and already established. Remaining activities include validation processes and potential additional scale-up in parallel with Phase III trials, leading to the BLA filing.
Q:Review of Unclear Management Responses
A:Management avoided providing specific updates or clarity on potential developments in the EGFR bispecific class for HPV16-positive head and neck cancer.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Addo Dr
Advances biomarker
Clinic Dana
Dana Farber
Dr overview
Dr update
EU uptake
FDA requirement
Farber Yale
HPV cancer
Institute trial
Interleukin antibody
JCO
Oncology
amendment
approval
cell
head neck
market
need treatment
option combination
patent
patient
pleasure
potential
progress
prostate cancer
protection
release result
result trial
survival
therapy
trial PDSADC
tumor
PDSB Transcript
PDS Biotechnology Corporation (PDSB) Q1 2026 Earnings Call Transcript
Unknown5-13
The earnings call presents a mixed outlook. Positive aspects include new patents for PDS0101 and reduced net loss, suggesting improved financial health. However, significant risks exist, such as the VERSATILE-003 trial amendment and early-stage PDS01ADC trials. The Q&A session highlighted management's evasiveness on certain topics, raising concerns. Overall, the company's financial constraints and pending trial results maintain a neutral sentiment.
PDS Biotechnology Corporation (PDSB) Q4 2025 Earnings Call Transcript
Unknown3-30
The earnings call lacked detailed operational, strategic, and financial updates, which can lead to uncertainty. The amendment to the Phase III trial introduces potential risks and uncertainties. The absence of revenue, margin, and cash flow information, along with unclear management responses in the Q&A, suggests a lack of transparency. These factors are likely to result in a negative market reaction.
PDS Biotechnology Corporation (PDSB) Q3 2025 Earnings Call Transcript
Unknown11-13
The earnings call reveals financial constraints, with a net loss and declining cash reserves, raising sustainability concerns. The VERSATILE-003 trial pause and lack of clarity on cost savings add uncertainty. The Q&A highlighted management's vague responses on key issues, such as trial adjustments and strategic interests, which may worry investors. Despite some positive developments in trials, market competition and reliance on external collaborations pose risks. Overall, these factors suggest a negative sentiment, likely resulting in a -2% to -8% stock price movement.
PDS Biotechnology Corporation (PDSB) Q2 2025 Earnings Call Transcript
Unknown8-13
The earnings call summary presents a mixed picture: positive developments in clinical trials and collaborations, but financial challenges persist. The Q&A section highlights promising trial data and competitive positioning, yet management's vague responses and financial strain (net loss increase, cash balance decline) raise concerns. No new partnerships or major strategic shifts were announced, and the lack of guidance on key trials adds uncertainty. Considering these factors, the stock price is likely to remain stable, leading to a neutral prediction.
PDSB Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
